<DOC>
	<DOCNO>NCT00066274</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different combination may kill tumor cell . PURPOSE : This randomized phase II trial study combination chemotherapy contain irinotecan oxaliplatin see well work compare two standard combination chemotherapy regimens treat patient unresectable metastatic colorectal cancer .</brief_summary>
	<brief_title>Comparison Combination Chemotherapy Regimens Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy , term response rate ( partial response complete response ) , irinotecan oxaliplatin v irinotecan , fluorouracil , leucovorin calcium v oxaliplatin , fluorouracil , leucovorin calcium patient metastatic colorectal cancer . - Compare progression-free survival patient treat regimen . - Compare tolerability regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive irinotecan IV 90 minute oxaliplatin IV 2 hour day 1 . - Arm II : Patients receive irinotecan IV 90 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour day 1-2 . - Arm III : Patients receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour day 1-2 . In arm , treatment repeat every 2 week 26 course absence disease progression unacceptable toxicity . Quality life assess baseline every 3 month 1 year . Patients follow 2 month . PROJECTED ACCRUAL : A total 80 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal carcinoma Metastatic disease Not amenable surgery Unidimensionally measurable disease No bone metastases No brain metastases PATIENT CHARACTERISTICS : Age 18 75 Performance status WHO 02 Life expectancy At least 12 week Hematopoietic Neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin great 1.25 time upper limit normal ( ULN ) ( 1.5 time ULN hepatic metastasis present ) SGPT SGOT great 3 time ULN ( 5 time ULN hepatic metastasis present ) Renal Creatinine great 1.25 time ULN Cardiac No concurrent cardiac abnormality would preclude study therapy Pulmonary No concurrent pulmonary abnormality would preclude study therapy Other Not pregnant nursing Fertile patient must use effective contraception No chronic enteropathy No prior cancer within past 5 year except carcinoma situ cervix curatively treat basal cell skin cancer No concurrent severe uncontrolled infection No obstruction partial obstruction would interfere study therapy No psychological , social , familial , geographical situation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent anticancer biological response modifier Chemotherapy No prior chemotherapy ( except adjuvant chemotherapy complete 6 month ago ) No prior irinotecan No prior oxaliplatin No concurrent chemotherapy Endocrine therapy No concurrent anticancer hormonal therapy Radiotherapy At least 4 week since prior pelvic radiotherapy No prior abdominopelvic radiotherapy Surgery At least 4 week since prior surgery No prior extensive intestinal resection ( i.e. , 1 prior hemicolectomy extensive resection small intestine ) Other No concurrent experimental medication No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>